ATTO (44) SLDB (27) IAM (49) CADL (34) ⌘ Pro Terminal →

4D Molecular Therapeutics Inc. (FDMT) — RQD Stock Rating Cockpit

$11.90 -6.89% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $11.73

4D Molecular Therapeutics Inc. (FDMT) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $706.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on FDMT Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is FDMT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, 4D Molecular Therapeutics Inc. (NASDAQ: FDMT) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $11.90 (-6.89% 1D, market cap $706.0M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, FDMT ranks #406 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does FDMT compare to ATTO and SLDB in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), FDMT carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -28.3%. By comparison, ATTO (Attovia Therapeutics Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC —, cap $697.1M) and SLDB (Solid Biosciences Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $685.2M). Among the 5-stock peer group, FDMT leads on earnings multiple (N/A) while FDMT leads on capital efficiency (-28.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for FDMT?

▼

Per FDMT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001650648), 4D Molecular Therapeutics Inc. generated $85.2M in revenue (+230194.6% YoY), -$140.1M in net income, and -$109.6M in free cash flow against $566.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $11.73 (-1.43%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE-5.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for FDMT)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (45/100 Composite)

🔍 WHY FDMT SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (31% of score)

Altman Z-Score 5.17 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (22% of score)

FRED Regime × Technicals: 50% of 52W Range • RSI-14 at 50.4 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$13.00-5.5% Next Q

Q2 (-2Q)

Grade C-$12.29-10.3% Next Q

Q3 (-1Q)

Grade D$11.03+7.9% Next Q

Current

Grade D$11.90-6.3% Hist 90D α

Trajectory: C- (53) → D (45)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a FDMT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While FDMT currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($13.65) and Max Pain ($12.50) forces dealer call-delta covering toward $17.78.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $FDMT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “FDMT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 45%NO 55%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

50.430 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

5.17>3.0 Fortress Safe

PIOTROSKI F-SCORESOLID CORE (5–6)

5 / 99-Pt Accounting

52-WEEK LASER RANGE50% OF RANGE

L: $7$11.90H: $17

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 9 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 12 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: C-RQD 24 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on FDMT

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (45)

-28.3% ROIC with 42.0% gross margin and -15.53% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (70)

Altman-Z 5.17 and Piotroski 5/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (37)

12/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like FDMT

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring FDMT)

✓Walkthrough of FDMT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

FDMT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +26.06%▲ ASCENDING CHANNEL

2026-11-02O $12.93H $12.93L $11.90C $11.90VOL 848.9K

RES: $17.35SUP: $10.74SMA50: $13.65SMA200: $10.90

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

FDMT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 FDMT Butterfly Map → + Track FDMT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on FDMT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for FDMT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for FDMT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (FDMT)

Health Care Rank #406 of 1016 ⚔️ ATTO vs FDMT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (FDMT vs. ATTO, SLDB, IAM, CADL)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, 4D Molecular Therapeutics Inc. (FDMT) ranks #406 by composite RQD confidence (45/100, grade D) and #399 by equity capitalization ($706.0M). Within this direct 5-issuer industry benchmark cohort, FDMT leads on earnings valuation at N/A trailing P/E, while FDMT leads on capital efficiency and profitability with -28.3% ROIC and — gross margin. IAM currently holds the highest overall quantitative score in the immediate peer group at 49/100 (D) compared with FDMT at 45/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
FDMT ACTIVE 4D Molecular Therapeutics Inc.	D	45/100	—	—	-28.3%	-6.89%	$706.0M	Benchmark Subject
ATTO Attovia Therapeutics Inc.	D	44/100	—	—	—	-0.52%	$697.1M	/atto-vs-fdmt →
SLDB Solid Biosciences Inc.	E	27/100	—	—	-35.0%	-2.97%	$685.2M	/sldb-vs-fdmt →
IAM Iambic Therapeutics Inc.	D	49/100	—	—	—	-5.95%	$676.9M	/iam-vs-fdmt →
CADL Candel Therapeutics Inc.	E	34/100	—	—	-35.0%	-3.70%	$661.9M	/cadl-vs-fdmt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001650648

In its most recent audited fiscal period (FY2025, filed 2025-12-31), 4D Molecular Therapeutics Inc. (FDMT) reported GAAP revenue of $85.2M (+230194.6% vs. FY2024 revenue of $37.0K , and +311.2% cumulative change since FY2023) , GAAP net income of -$140.1M, operating cash flow of -$109.1M, and free cash flow of -$109.6M (+20.8% YoY). On the balance sheet, FDMT closed FY2025 with $566.7M in total assets against $0 in total debt (Altman Z-Score: 5.17, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$85.2M	-$140.1M	-$109.1M	-$109.6M	$566.7M	$0
FY2024 (FY)	2024-12-31	$37.0K	-$160.9M	-$134.6M	-$138.4M	$560.4M	—
FY2023 (FY)	2023-12-31	$20.7M	-$100.8M	-$75.8M	-$75.8M	—	—

3. FDMT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is FDMT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does FDMT compare to ATTO and SLDB in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for FDMT?

Where is FDMT trading relative to its 50-day, 200-day, and 52-week technical levels?

FDMT last traded at $11.90 (-6.89% on volume of 683,520 shares), positioning the stock -12.82% below its 50-day simple moving average ($13.65) and +9.17% above its 200-day simple moving average ($10.90). Across its 52-week range of $6.96 to $16.93, FDMT sits at the 49.5% percentile with a 14-day RSI of 50.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($10.41 to $13.39).

FDMT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell FDMT stock right now?

4D Molecular Therapeutics Inc. (FDMT) currently earns a Roarable Rating of D (Sell — SELL) with 45/100 RQD Confidence. Stretched risk/reward at current multiples (-28% return on capital) under elevated 10-year interest-rate pressure.

What is FDMT's 12-month price target and RQD AI Jury consensus?

FDMT's 12-month base price target is $11.2 (range $8.74 to $17.78), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: FDMT RQD Cockpit FDMT 12M Forecast FDMT Earnings & Move FDMT Dividends & DRIP FDMT Insiders & 13F FDMT Whale Options FDMT Profit Sankey FDMT News & Why

ROARABLE RATING BRIEF • RQD 45/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

FDMT — 4D Molecular Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:33:39Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, FDMT scores 45 out of 100, earning a letter grade of D and the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are:

Fundamental Cash Engine — 9 / 20: Per the RQD rating, ROIC is -28.3% and FCF yield is -15.53%. The cash engine is currently consuming capital rather than generating it.
Whale 13F Flow — 9 / 20: Per the RQD rating, institutional accumulation and options positioning scored below midpoint. The source data contains no 13F holder detail to confirm the drivers.
Insider Conviction — 3 / 20: This is the weakest pillar. The news wire includes a reported insider sale by David Kirn of 58,333 shares and a sale by the CLO of $20,993, which align with the low insider score.
Macro Regime Fit — 10 / 20: Per the RQD rating, beta is 1.0 and the score reflects sector sensitivity.
Forensic Balance Sheet — 14 / 20: Per the RQD rating, Altman Z is 5.17, Piotroski F is 5/9, and Debt/Equity is 0.5. This is the strongest pillar and reflects a relatively sound balance sheet despite operating losses.

For a prospective investor, the picture is a company with a reasonable balance sheet funding a deeply loss-making operation. Upside drivers are the two pivotal readouts for 4D-150 that the news wire says are expected in 2027. Valuation is difficult to anchor because operating margin is -60% and P/E is not available in source data. The weak insider and cash-flow pillars point to distribution risk, so the score argues for caution rather than accumulation on current evidence.

Business

Per the profile, 4D Molecular Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. The source data does not describe its customers or detailed product lines beyond the news references to 4D-150, a gene therapy targeting wet AMD. Revenue in FY 2025 was $85.2M per the SEC financials, though the source data does not break down how that revenue is generated.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$85.2M	$-159.5M	$-140.1M	N/A	$-109.6M	$60.2M	$0.0M
FY 2024	$0.0M	$-187.8M	$-160.9M	N/A	$-138.4M	$149.3M	N/A
FY 2023	$20.7M	$-112.9M	$-100.8M	N/A	$-75.8M	N/A	N/A

Per the market data, gross margin is 0%, operating margin is -60%, and net margin is -60%, with ROIC at -28.3%. Per the RQD rating, the Altman Z-Score is 5.17 and the Piotroski F-Score is 5/9. Per the SEC financials, cash declined from $149.3M in FY 2024 to $60.2M in FY 2025 against zero reported debt in FY 2025, which indicates the balance sheet is funding losses from reserves.

Recent Catalysts & News Wire Analysis

Per the recent news wire, the principal catalysts are:

An Analyst/Investor Day slideshow dated 2026-10-21 (Seeking Alpha).
Coverage of 4D-150 as a wet AMD gene therapy, with the TradingView report stating that two pivotal readouts are expected in 2027.
Insider sales: a CLO sale of $20,993 (Investing.com) and a sale of 58,333 shares by David Kirn (GuruFocus).
An analyst-conflict piece in The Globe and Mail.

Risk watch items are the insider selling and the cash decline. Per the Butterfly Supply-Chain Graph, there are no supply-chain links and no proprietary signals, so no butterfly-derived catalysts are available.

Open Questions

What are the specific revenue sources behind FY 2025 revenue of $85.2M, and how much is recurring?
What is the cash runway given the FY 2025 cash balance of $60.2M and FCF of $-109.6M?
What is the pivotal readout design and success criteria for 4D-150 in 2027?
What is the full insider transaction history, and does it include any purchases?
What is the institutional holder base and recent 13F change direction?

FDMT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for 4D Molecular Therapeutics Inc. (FDMT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to FDMT Debate Forum (3) ↓

🟡 MARKET WIRE Seeking Alpha • 6h ago

4D Molecular Therapeutics, Inc. (FDMT) Analyst/Investor Day - Slideshow (NASDAQ:FDMT) 2026-10-21

Seeking Alpha report covering 4D Molecular Therapeutics Inc. (FDMT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 9h ago

Scott Bizily, 4D Molecular Therapeutics CLO, sells $20,993 in stock

Investing.com report covering 4D Molecular Therapeutics Inc. (FDMT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 12h ago

4D Molecular Therapeutics Targets Wet AMD Injection Burden With 4D-150 Gene Therapy

Yahoo Finance report covering 4D Molecular Therapeutics Inc. (FDMT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GuruFocus • 15h ago

Insider Sell: David Kirn Sells 58,333 Shares of 4D Molecular The

GuruFocus report covering 4D Molecular Therapeutics Inc. (FDMT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 18h ago

FDMT: 4D-150 targets continuous wet AMD control, with two pivotal readouts expected in 2027

TradingView report covering 4D Molecular Therapeutics Inc. (FDMT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Globe and Mail • 21h ago

Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (FDMT), Pfizer (PFE) and Incyte (INCY)

The Globe and Mail report covering 4D Molecular Therapeutics Inc. (FDMT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Officer David Kirn plans to sell 58,333 shares of 4D Molecular Therapeutics (FDMT).

Stock Titan report covering 4D Molecular Therapeutics Inc. (FDMT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance UK • 1d ago

4D Molecular Therapeutics, Inc. (FDMT) Seasonal returns chart

Yahoo Finance UK report covering 4D Molecular Therapeutics Inc. (FDMT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

FDMT Bull vs. Bear Conversation Board — What's Your Call at $11.90?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON FDMT 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $11.25 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is FDMT (D • RQD 45/100) a Buy at $12.78?

Welcome to the FDMT (4D Molecular Therapeutics Inc.) Roar Pit. Current RQD Composite is 45/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $9.59 (-25.0%)

Spot @ $12.78

Pump the brakes on FDMT — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on FDMT, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless 4D Molecular Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MI MidwestValue Verified K Arena Trader 🐂 BULLISH 🎯 Target: $15.72 (+23.0%)

Spot @ $12.78

FDMT cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on FDMT, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $12.78 (52-wk range $6.96 - $16.93), any beat on forward guidance forces shorts and underweight funds to chase.